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Dr Carolyn R. Reed (Charleston, SC). When PET came on the
scene, all of us hoped that it would remarkably improve the
accuracy of clinical staging. Although PET, especially integrated
PET/CT, has increased staging accuracy, the multi-institutional
studies have somewhat dampened our initial enthusiasm. As we
have seen in other papers today, we must look at subsets of patients
to refine the utility of PET.
Recently, there has been a new focus on the intensity of FDG
uptake in an individual tumor as a surrogate marker of the biologic
behavior of that tumor. This is particularly attractive because
assessment of such things as cell proliferation markers and gene
expression profiling require tissue samples. Dr Downey’s paper
gives us insight into the true usefulness of PET and also, I believe,
its limitations.
Dr Downey, I think your study corroborates several known
things: the size cut-off point between T1 and T2 tumors should be
lower than 3 cm; small adenocarcinomas have better prognosis,
perhaps because histologies such as BAC and other GGOs are
included; and most importantly, postoperative pathologic stage is
still the key.
I do have one problem with the preoperative use of SUVMAX
because although at your institution an SUVMAX of less than 4.3
might be predictive of good prognosis, that might not be the case
at other institutions. SUV is a continuous variable, and a binary
cut-off point might not be appropriate. There are many factors, as
we all know, that affect the SUV determination. Therefore my first
question is this: How do we use your finding of an SUVMAX of 4.3
as a prognostic cut-off point? Should we establish our own insti-
tutional cut-off point?
Dr Downey. This is a problem that has been addressed before,
and it is a very important point. The standardized uptake value is
not standardized between institutions. It is just standardized within
an institution. Therefore a tumor measured to have an SUV of 4.3
in one institution might have a different measurement at another
institution. There is interest in the nuclear medicine field for trying
to come up with equipment similar to the phantom used in CT
scanning that would allow standardization of SUV measurements
between institutions, but thus far, there is no means of standard-
izing, and this just should be taken as a relative value.
The second question is about SUV being a continuous variable.
I believe that there are good reasons to consider treating SUV as a
binary variable. We have observed that patients who have an SUV
of less than 5 almost never have nodal metastases. In our earlier
article with 100 patients, there are 33 patients who had an SUV of
less than 5, and only one of them had a lymph node metastasis.
There are 67 patients with an SUV of greater than 5, and the
incidence of nodal metastases was 33%. We have made a similar
observation in patients with esophageal cancer that prognosis is
best defined by dichotomizing around an SUV of 5. Therefore
there might be a binary cut-off point, but this will require further
research.
Dr Reed. You say that 3 clinical variables are available pre-
operatively to give 3 prognostic categories, yet many of us do not
currently perform biopsies on small, highly PET-positive periph-
eral lesions before surgical intervention. You also used pathologic
T size and not a CT estimate. Do you now recommend biopsy of
all lesions to adequately prognosticate and perhaps, in addition,
supply tissue for other markers?
Dr Downey. Again, this is a very important point. To deter-
mine the prognostic value of PET SUV, what I did was to compare
PET with what would be the optimal combination of standard tests,
which would be if the fine-needle aspiration preoperatively told
you everything about the histology that the final pathology was
going to show you, and also radiographically they were able to
determine the same size that was determined by means of pathol-
ogy. Despite this being the best standard that could possibly be
obtained, PET still turned out to be an independent predictive
variable. Obviously, there is going to be degradation from that
high standard in common practice because if we try to measure
things radiographically, it will only approximate pathologically
measured size, and histology defined from a fine-needle aspiration
is never going to be as good as the final pathology. Therefore I
believe that the PET SUV might turn out to be the best indepen-
dent prognostic variable that we have available in the preoperative
period. I am not advocating needle biopsies in everyone.
Dr Reed. It was hoped that FDG-PET could be a useful tool in
identifying patients at high risk of recurrence with each stage,
particularly resected stage I and II disease. Because of your find-
ings, would you still favor a prospective multi-institutional study
looking at this issue in a homogeneous population of patients; that
is, those with surgically resected stage I and II disease?
Dr Downey. There are about 10 to 12 articles that have been
published looking at the prognostic significance of PET SUV.
Most recently there was Dr Cerfolio’s article from Alabama in
which he found results that were different from ours. He found that
the PET did predict survival independent of pathologic staging. It
was a smaller group of patients but still a very substantial number.
I have not talked to him to figure out why we have the results that
we have and he has results that he has. Therefore I would still
consider this an open question for development. I do not know
whether it requires a multi-institutional study.
Dr Reed. Finally, how would you use PET to stratify for
neoadjuvant therapy? Tell us what you would recommend for a
patient with clinical T2 N0 squamous cell carcinoma with an
SUVMAX of 10.
Dr Downey. We have a very low threshold for recommending
patients for neoadjuvant therapy; however, I think we might have
identified a group of patients who might not benefit. Although it is
somewhat of a philosophical question, it is not clear whether it
would be worth giving induction therapy to the group with the best
prognosis, who have a 3-year survival of 86%. We might be able
to reduce the number of patients who get referred for induction
therapy.
Dr Reed. I believe, finally, that this is a very important paper
because it refines the use of PET, and I want to congratulate Dr
Downey on a very nice presentation. Thank you very much.
Dr Downey. Thank you.
Dr Robert J. Cerfolio (Birmingham, Ala). Dr Miller said I can
only ask one quick question, and therefore I will try to ask you 2
quick questions.
First of all, I congratulate you on your findings, and I think our
findings are relatively similar, and we are corroborating one an-
other. There are some specifics. You grouped stage II and stage III
disease together. That might have been a factor, and we can talk
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about that later. But I think we do need a multi-institutional
prospective study, and I think we should look at neoadjuvant
therapy for the patients with stage IB disease. The patients with
stage IB disease are the ones we all know do poorly, and I think the
SUVMAX helps you identify the patients with stage IB disease who
do poorly. Therefore this is my chance to try to get all the world’s
experts who are here to participate in a study like that, which I
think we really need to do.
The second thing is that we need to get the SUVMAX to be the
same at different institutions. It is not that hard to do. The nuclear
radiologists tell us they can do it. Then an SUVMAX in Brazil will
be the same as an SUVMAX in New York or Birmingham.
Could you comment on the role of a prospective study looking
at neoadjuvant chemotherapy for a patient with stage IB disease
and how we would identify the patients with stage IB disease with
integrated PET/CT and not dedicated PET?
Dr Downey. I did not mention it, but in this group we transi-
tioned from just PET to PET/CT in the middle of this study at our
own institution. I think one of the most interesting findings was the
statistical phenomenon of an interaction that was seen in the
patients with clinical stage IB disease, such that if it is a discrimi-
nant, it is maybe most effective in telling you who is a good- and
a poor-risk patient with clinical stage IB disease. I am not sure that
I would use it to start off a multi-institutional trial involving
induction therapy at this point because there is no defined role for
induction therapy. I think that we need to simply validate that we
can identify preoperatively patients with something that correlates
with pathologic stage, and that would be best done across institu-
tions. What I think we have here is that it does show there is no
relationship between PET and pathology and therefore no addi-
tional benefit of adding PET to pathology; therefore we can use
pathologic stage as the gold standard, and it would be a relatively
straightforward study to do to define prognostic variables preop-
eratively, have surgeons assign a clinical stage, and then just find
out what they find at the operation a week later and see how close
we can get. Then after we have done that, shown what variables
work, then we can decide who should get induction therapy.
Dr Daniel L. Miller (Atlanta, Ga). Although I enjoyed your
presentation, I think the most important point about this is when
we look at visceral pleural invasion because we are getting to these
smaller tumors—2 cm, 1.5 cm—and they are peripheral, and they
are going to have a significant amount of visceral pleural invasion.
Your greatest crossover group was stage IA to IB disease, and I
think that probably was not measurement but was probably related
to visceral pleural invasion. We are looking back now to our own
data. There are actual lung cancers less than 3 cm with visceral
pleural invasion that are actually doing worse than those of 4 cm
without visceral pleural invasion. Did you look at visceral pleural
invasion at all?
Dr Downey. I do have a slide that showed that, but I did not
display it. The 2 areas, sort of the move from clinical to pathologic
stage, if we break it down by T, N, and M, it was not in the N and
the M category, it was in the T category, and it was not on
measured size. The majority of them, as you pointed out and you
picked up on, were going from T1 to T2 or T1 to T4. Less so, but
still those are the major areas that fell off.
Dr Miller. Well, I think it is more important now with our
pathologists with determining visceral pleural invasion at the time
of resection because they are all getting adjuvant treatment now for
stage IB disease, and if you are going to do a stage IB disease study
preoperatively, we are going to miss some patients because we are
not going to be able to identify that visceral pleural.
Dr Anthony P. Yim (Shatin, Hong Kong). Dr Downey, I really
enjoyed your paper.
Did you look at delayed SUV values apart from the SUVMAX,
and do they affect the outcome?
Dr Downey. No. Our nuclear medicine physicians have been
very interested, and I have been sort of peripheral to that work, in
trying to see whether there are any other parameters that work
better than the SUVMAX. They have tried integrating the SUV
across the tumor and various things, and they have never found
anything that they think is better in any of these data sets than the
SUVMAX of the primary site of disease.
Dr Yim. Just to comment, in my locality we still see a lot of
inflammatory disease, such as tuberculosis, and we pay a lot of
attention to the delayed value.
Dr Frank C. Detterbeck (New Haven, Conn). Rob, I have just
a comment. Maybe you know the answer to this better than I do,
but my understanding is that there are a lot of factors that go into
SUV, and I do not think it is as simple as just standardizing the
machine at one institution versus that at another. It has to do with
the activity of the FDG, the timing between the injection, and
when you scan. It also has to do with the size of the lesion. Once
the lesion is less than 2 cm, you have to correct for the size of the
lesion because otherwise you will underestimate it. It also has to do
with where in the lung the lesion is because if there is a lot of
movement, then you do the volume averaging on the PET scan just
like you do on the CT scan. Therefore there are a lot of factors. My
understanding is that determining a reproducible and reliable SUV
value is not at all straightforward or simple, but perhaps you know
more about this than I do or perhaps Rob Cerfolio does.
Dr Downey. I think actually Dr Cerfolio said it would be easier
to standardize between institutions. I do not think it will be
particularly that easy. It is the time between the injection versus
when it is scanned, the dose that is given. Your point about the
tumor size, though, I think is a very important one that has nothing
to do with the institution. The smaller the lesions are, the more
there is going to be a volume averaging. The CT scan is obtained
over the length of time that the PET scan lasts, and there will be
sort of a movement up and down, both smearing out the sort of
SUV value over a larger volume—relatively larger volume—but
also degrading the quality of the CT scan. Therefore these are all
things that have to be taken into account as we work on the
preoperative clinical variables.
Dr John Howington (Cincinnati, Ohio). Rob, nice presenta-
tion. There was discussion about needle biopsies and no-needle
biopsies, and then the discussion led over into doing induction
therapy for lesions with a high SUV. Being in Cincinnati, in the
histoplasma belt, I just cringe at the thought of a patient with a
solitary pulmonary nodule, with SUVs of 8, 9, and 10 that are
histoplasma, being mistakenly treated for cancer. The idea of
doing induction therapy in a patient without a tissue diagnosis is
hard for us to swallow.
Dr Downey. I was not advocating or arguing against fine-
needle aspirations. That was not the point of the paper.
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Dr Cerfolio. Well, since you invited me to answer that, Frank, I
would say that the formula that goes into the SUVMAX is not depen-
dent on where the nodule is located. It is not dependent on the size of
the nodule. It is a very specific formula that looks at the activity at a
pixel that can add some of those variables. Actually, those are prob-
ably less than 10% differences from talking to the GE guys who do
this every day. It has to do with the weight of the patient and the
injected dose, and those are very easily corroborated among centers
and organized. Therefore I do not think it is that hard to get an
SUVMAX to be the same across the world. I will shut up now.
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